Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Masimo Acquires Lidco For $40.3M In Cash, Adds Complementary Hemodynamic Monitoring Tech

Executive Summary

Masimo’s planned buyout of Lidco could help expand its footprint into the US.

You may also be interested in...



Market Brief: Blood Gas Monitoring Systems Market Expected To Reach $4.9Bn By 2023

The global market for blood gas monitoring systems is expected to grow 6.1% annually to reach $4.9bn in 2023, driven by the rising prevalence of chronic diseases, the aging population, and pressure on medical device makers to introduce smart devices that improve outcomes while reducing cost of care.

Canary Speech’s Voice AI Can Help Detect Alzheimer’s With 40-Second Conversation

AI voice tech start-up Canary Speech is developing algorithmic models for detecting behavioral health, progressive neurological and cognitive diseases based on a 40-second recording of speech. Medtech Insight caught up with Canary CEO Henry O’Connell at DHIS West to learn more about the company and its plans.

SVB’s Milo Bissin Predicts ‘Reckoning In 2024’ For Health Care Companies With Sky-High Valuations

VC funding will remain challenging for many in the health care industry, Silicon Valley Bank’s market manager Milo Bissin told attendees at the recent DHIS West conference. Companies focusing on promising areas such as AI-powered technologies, women’s health and value-based care likely have the best chances to draw investors’ attention.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel